Atopic Dermatitis / Eczema Clinical Trials

Currently Enrolling

  • Regeneron Protocol R668-AD-1762: A prospective observational study of adult patients receiving Dupixent® for atopic dermatitis. For patients 12 years and older.  |  Learn More »  |  Request to Join This Study »

  • Regeneron Protocol R668-AD-1539 Part B: A Phase 2/3 study investigating the Pharmacokinetics, safety, and efficacy of a biologic IL-4 inhibitor (Dupilumab) in patients aged ≥6  months to <6 years  |  Learn More »  |  Request to Join This Study »


  • Dermira Protocol DRM06-AD06: A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab (a biologic IL-13 inhibitor) when used in combination with topical corticosteroid treatment in patients with moderate-to-severe atopic dermatitis. For patients 12 years of age or older.   |  Learn More »  |  Request to Join This Study »

  • Dermira Protocol DRM06-AD17: A Phase 3, open-label, single-arm study to assess the safety and efficacy of Lebrikizumab (a biologic IL-13 inhibitor) in adolescent patients with moderate-to-severe atopic dermatitis. For patients 12 through 17 years old.   |  Learn More »  |  Request to Join This Study »

  • Sanofi Protocol OBS15333: Prospective, observational, longitudinal study in pediatric patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not medically advisable. For children up to age 11.   |  Learn More »  |  Request to Join This Study »

 

Active / Not Enrolling

  • Lilly protocol I4V-MC-JAIX: A multicenter, open-label, Phase 3 Study to evaluate the efficacy and safety of Baricitinib in adult patients with moderate-to-severe atopic dermatitis.  | Learn More »  |  No Longer Enrolling

  • Pfizer Protocol B7451015: A Phase 3 multi-center, long-term extension study investigating the efficacy and safety of Abrocitinib, with or without topical medications, administered to subjects aged 12 years and older with moderate-to-severe atopic dermatitis.  |  Learn More »  |  No Longer Enrolling

  • Abbvie Protocol M16-813: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate Risankizumab in adult and adolescent subjects with moderate-to-severe atopic dermatitis.  |  Learn More »  |  No Longer Enrolling

 

View Other Clinical Trials